APLUSA’s Post

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes "Conclusions and Relevance In this study, GLP-1RAs were associated with lower risks of specific types of OACs compared with insulins or metformin in patients with T2D. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain OACs." https://lnkd.in/eSeb5dHg

I find it interesting that GLP-1 drugs for Type 2 diabetes might help prevent some cancers. A recent study in JAMA Network Open shows that these newer medications, used for diabetes and weight loss, could reduce the risk of obesity-related cancers more than insulin does. This study looked at the health records of over 1.6 million patients over 15 years and found that drugs like Victoza could lower the chances of getting colon cancer. However, these drugs didn’t do better than metformin, an older diabetes medicine known to reduce cancer risk. Interestingly, GLP-1 drugs didn’t lower the risk of post-menopausal breast cancer and seemed to increase the chance of kidney cancer compared to metformin. Still, their potential in preventing cancer is exciting and shows how diabetes treatments are evolving. #Diabetes #Cancer #obesity #healthcare

"GLP-1 medications such as Ozempic and Wegovy have exploded in popularity for their weight loss benefits and now new research is showing the medications may help with another condition, cancer. People with Type 2 diabetes who were treated with GLP-1 medications were found to be less likely to be diagnosed with obesity-associated cancers than people treated with insulin or metformin, according to a new study published July 5 in the medical journal JAMA Network open." Continue to read "What to know about new study showing weight loss drugs can lower cancer risk" #GLP1Medications #weightloss #diabetes #Cancer #yourhealthmatters #buylocal #shoplocal #yousaveonmeds

"In a significant medical discovery, a class of #diabetes medications, including the widely-used drug #Ozempic, has been linked to a decreased risk of numerous obesity-associated cancers. The findings indicated a notable reduction in the risk of developing 10 out of 13 types of #cancer examined in the study. The cancers showing decreased risk include those of the kidney, #pancreas, oesophagus, ovaries, liver, and colorectum." #obesity #obesitycare #obesitymedication #lifestylemedicine

GLP-1 agonists, including Ozempic, reduce the risk of certain obesity-related cancers. Patients with Type 2 diabetes on these drugs had significantly lower risks of 10 out of 13 cancers studied. This may break the link between obesity and cancer and could lead to more doctors prescribing these drugs over insulin for diabetes treatment. https://lnkd.in/d59nrz4Z

Industry Update: A study published in #TheBMJ has found that #GLP1 receptor agonists, such as Novo Nordisk's #Ozempic and #Victoza, do not seem to increase the risk of #thyroidcancer. The research, conducted by #KarolinskaInstitutet in Sweden, analyzed data from around 145,000 patients treated with GLP-1s and compared them to over 290,000 patients receiving other #diabetes treatments.   Over an average follow-up period of just under four years, the study found no significant increase in thyroid cancer risk among GLP-1 users. Despite the positive findings, the researchers noted that there could still be potential risks in smaller, unstudied patient groups. GLP-1 therapies, known for managing #diabetes and #obesity, are also under review for potential links to #suicidalideation and #selfharm, but regulatory bodies like the #EMA and the #FDA have not found conclusive evidence of such associations.   #MedicalResearch #HealthNews #PharmaNews #Diabetes #Obesity Novo Nordisk   Detailed News: https://lnkd.in/dBEABgWA    Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Starting their journey as #antidiabetes medicines, #SGLT2 and #GLP1 products have emerged as the #wonderdrugs for #cardiovascular, #renal and #metabolic disorders. And the list of their benefits across a range of diseases is growing, steadily. A few weeks ago, there was some noise about GLP-1 drugs causing suicide ideation. The EU regulatory authorities independently investigated and concluded that these medicines are NOT associated with suicidal thoughts. The US regulatory body #FDA has also reached the same conclusion after a preliminary evaluation. It is a credit to companies like #boehringer, #novonordisk, #elililly, #astrazeneca who spent several hundred millions of dollars to establish develop a vast body of evidence behind medicines such #Ozempic, #Trulicity, #Jardiance, #Farxiga, #Bydureon, #Mounjaro and others. Regardless, both these categories of medicines have been very useful in providing succor to patients with #cardiovascular and/or #renal and/or #metabolic disorders. Going forward, #drugdevelopers are combining the existing SGLT2 and GLP-1 medicines with other drug classes to increase the depth and breadth of #medicalbenefits - something we all can look forward to! #GLP1 #GLP1Agonists #SGLT2 #SGLT2inhibitors #CVRM #raslss # #healthcare #Pharmacology #Endocrinology #Medicine #HealthcareInnovation

GLP-1 receptor agonists (medications designed to manage #obesity and type 2 #diabetes) have recently been under a lot of discussions regarding the risk of #thyroidcancer and suicidal ideation /self-harm in these patients. A study published in the #BMJ looked at health data for 145,410 patients living in Denmark, Sweden and Norway who were prescribed #GLP1 medications (such as semaglutide, liraglutide) and another 291,667 patients who were treated with DPP4 inhibitors. Each group was compared and followed for an average of about four years: 76 participants treated with GLP-1 drugs and 184 participants treated with DPP4 inhibitors developed thyroid cancer. The researchers determined that because the incidence rate was so low, GLP-1 use was not associated with a substantially increased risk of developing thyroid cancer, though they couldn’t “exclude a small increase in risk.” In addition, GLP-1 therapies are also being reviewed for their potential risk of increasing suicidal ideation and self-harm. The #EMA kicked off its probe in July 2023 and in Nov 2023, the Pharmacovigilance Risk Assessment Committee (#PRAC) emphasized the need for additional data regarding these signals as a follow-up to the July 2023 assessment. In its recent PRAC review in April 2024, the agency concluded that there is no connection between suicidal thoughts and GLP-1-based drugs after an extensive investigation. Follow us for more such industry news! #industrynews #GLP1s #EMA #raslss #pharmnews

More good news for GLP-1 RAs!!!

GLP-1 receptor agonists, a popular class of drugs including Novo Nordisk's #Ozempic (semaglutide) and #Victoza (liraglutide), do not seem to increase the risk of #thyroidcancer, according to a study published in The #BMJ. The Scandinavian study conducted by researchers at #KarolinskaInstitutet analyzed data from national registries in #Denmark, #Norway, and #Sweden. It compared around 145,000 patients treated with GLP-1s to over 290,000 patients using other diabetes treatments. The study found no significant increase in thyroid cancer risk among patients using GLP-1s over a follow-up period of nearly four years. The research offers strong support that GLP-1 analogs are not linked to an increased risk of thyroid cancer. However, the researchers caution that some subtypes of thyroid cancer may carry risks for smaller, unstudied patient groups. GLP-1 receptor agonists are a leading class of diabetes and obesity medications, primarily represented by Novo's #semaglutide and Lilly's #tirzepatide. These companies are expected to control around 80% of the multibillion-dollar market by 2030. GLP-1s have been flagged for potential safety issues, including associations with suicidal ideation and self-harm, which both the #EuropeanMedicinesAgency and the #FDA are investigating. However, neither regulator has found conclusive evidence to support the link. #MedicalResearch #Pharmaceuticals #Diabetes #Obesity #GLP1 Novo Nordisk Eli Lilly and Company